Abstract 112P
Background
Historical data has demonstrated a synergistic anti-tumor response with the combination of immunotherapy, chemotherapy, and anlotinib for extensive-stage small-cell lung cancer (ES-SCLC). However, real-world evidence supporting this combination regimen is lacking. Therefore, we initiated a multicenter real-world study to evaluate the efficacy and safety of serplulimab (an anti-PD-1 mAb) combined with chemotherapy plus anlotinib for ES-SCLC patients.
Methods
Patients initially diagnosed with ES-SCLC who received serplulimab combined with chemotherapy and anlotinib between October 2020 and June 2024 were eligible for this study. The primary endpoint was overall survival (OS). The secondary endpoints were progress-free survival (PFS) and adverse events (AEs). Subgroup analyses were performed based on the different treatment lines.
Results
A total of 40 patients who received serplulimab combined with chemotherapy and anlotinib with a median age of 63 (range: 50-83) years were included in three centers. The main features included males (77.5%), smokers (67.5%), ECOG score of 1 (57.5%), and stage Ⅳ disease (87.5%). There were 28 patients received serplulimab as the first-line, 9 as the second-line, and 3 as the third-line. Anlotinib was administered to 5 patients in first-line, 13 in second-line, and 22 in third-line therapy. The median follow-up duration was 21.5 months (range: 5.2-46.7). The median OS from the initial diagnosis of all patients was 21.8 months (95%CI 15.6-NR). There was no significant difference in median OS between different anlotinib treatment lines (14.2 vs. NR vs. 21.8 months, P=0.737). The median PFS was numerically higher in patients receiving first-line combination therapy than those not treated with first-line anlotinib in combination (9.2 vs. 6.6 months, P=0.354). Any grade AEs occurred in 30 (75.0%) patients, with anemia being the most common (17, 42.5%). Grade ≥3 AEs were reported in 6 (15.0%) patients.
Conclusions
Our study revealed that serplulimab combined with chemotherapy and anlotinib as a front-line treatment regimen might benefit survival and is well-tolerated for ES-SCLC patients.
Legal entity responsible for the study
Jun Wang.
Funding
Clinical Research Capacity Building and Human Research Participants Protection Practice Platform (CCHRPP).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
63P - Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
Presenter: Bin Wu
Session: Poster Display session
Resources:
Abstract
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract